Making Quirem Medical B.V. a Wholly Owned Subsidiary
First written in FY2021-Q3. 3 of 6 entries say "Restated". Latest entry: FY2024-Q1.
No other company in this theme has enough history to compare yet.
- FY2024-Q1RestatedAnnual report
「The contingent consideration related to the acquisition of shares in クイレムメディカル B.V. depends on obtaining CE Mark certification for next-generation products and achieving specified performance metrics, among other factors, and payments of up to US$20 million may be made depending on the achievement of milestones.」
Continues to disclose contingent consideration of up to US$20 million for クイレムメディカル B.V., linked to obtaining CE Mark certification and achieving performance metrics. - FY2023-Q3RestatedAnnual report
「The contingent consideration related to the acquisition of shares in クイレムメディカル B.V. depends on obtaining CE Mark certification for next-generation products and achieving specified performance metrics, among other factors, and payments of up to US$20 million may be made depending on the achievement of milestones.」
Continues to disclose contingent consideration of up to US$20 million for クイレムメディカル B.V., linked to obtaining CE Mark certification and achieving performance metrics. - FY2023-Q2RestatedAnnual report
「The contingent consideration related to the acquisition of shares in クイレムメディカル B.V. depends on obtaining CE Mark certification for next-generation products and achieving specified performance metrics, among other factors, and payments of up to US$20 million may be made depending on the achievement of milestones.」
Continues to disclose contingent consideration of up to US$20 million for クイレムメディカル B.V., linked to obtaining CE Mark certification for next-generation products and achieving performance metrics. - FY2023-Q1SoftenedAnnual report
「The contingent consideration related to the acquisition of shares in クイレムメディカル B.V. depends on obtaining CE Mark certification for next-generation products and achieving specified performance metrics, among other factors, and payments of up to US$20 million may be made depending on the achievement of milestones.」
The cap on contingent consideration for クイレムメディカル B.V. was changed from the previously disclosed maximum of US$25 million to a maximum of US$20 million. - FY2021AchievedAnnual report
「July 2020: Acquired all assets of クイレム・メディカル B.V. in the Netherlands.」
The acquisition of all assets of クイレム・メディカル B.V. was completed in July 2020 and accounted for as an acquisition through a business combination in the current fiscal year, with contingent consideration disclosed. - FY2021-Q3First statedAnnual report
「The contingent consideration arising from business combinations relates to the acquisition of the large-bore hemostasis device business from メデオン・バイオデザイン社, the acquisition of shares in 易生科技（北京）有限公司, and the acquisition of shares in クイレムメディカル B.V., which became a wholly owned subsidiary during the nine-month period ended this third quarter. The contingent consideration related to the acquisition of shares in クイレムメディカル B.V. depends on obtaining CE Mark certification for next-generation products and achieving specified performance metrics, among other factors, and payments of up to US$25 million may be made depending on the achievement of milestones.」
For the first time, disclosed that クイレムメディカル B.V. became a wholly owned subsidiary during the nine-month period ended the third quarter. Contingent consideration of up to US$25 million was established, linked to obtaining CE Mark certification for next-generation products and achieving specified performance metrics.